Table 1. Relationship between preoperative HALP and LMR and the clinical-pathological data of patients.
| Characteristic | Total number, N (%) | HALP, N (%) | LMR, N (%) | |||||
|---|---|---|---|---|---|---|---|---|
| <48 | ≥48 | P | <6.3 | ≥6.3 | P | |||
| Age | 0.023 | 0.008 | ||||||
| ≥65 | 102 (42.0) | 51 (21.4) | 51 (21.4) | 84 (35.3) | 18 (7.6) | |||
| <65 | 136 (57.1) | 48 (20.2) | 88 (37.0) | 91 (38.2) | 45 (18.9) | |||
| Gender | 0.072 | <0.001 | ||||||
| Male | 150 (63.0) | 69 (29.0) | 81 (34.0) | 122 (51.3) | 28 (11.8) | |||
| Female | 88 (37.0) | 30 (12.6) | 58 (24.4) | 53 (22.3) | 35 (14.7) | |||
| Smoking history | 0.745 | 0.536 | ||||||
| Yes | 87 (36.6) | 35 (14.7) | 52 (21.8) | 66 (27.7) | 21 (8.8) | |||
| No | 151 (63.4) | 64 (26.9) | 87 (36.6) | 109 (45.8) | 42 (17.6) | |||
| Drinking history | 0.562 | 0.243 | ||||||
| Yes | 50 (21.0) | 19 (8.0) | 31 (13.0) | 40 (16.8) | 10 (4.2) | |||
| No | 188 (79.0) | 80 (33.6) | 108 (45.4) | 135 (56.7) | 53 (22.3) | |||
| Type 2 diabetes | 0.226 | 0.220 | ||||||
| Yes | 15 (6.3) | 4 (1.7) | 11 (4.6) | 9 (3.8) | 6 (2.5) | |||
| No | 223 (93.7) | 95 (39.9) | 128 (53.8) | 166 (69.7) | 57 (23.9) | |||
| Hypertension | 0.116 | 0.212 | ||||||
| Yes | 58 (24.4) | 19 (8.0) | 39 (16.4) | 39 (16.4) | 19 (8.0) | |||
| No | 180 (75.6) | 80 (33.6) | 100 (42.0) | 136 (57.1) | 44 (18.5) | |||
| Tumor size | 0.020 | 0.024 | ||||||
| ≥3 cm | 163 (68.5) | 76 (31.9) | 87 (36.6) | 127 (53.4) | 36 (15.1) | |||
| <3 cm | 75 (31.5) | 23 (9.7) | 52 (21.8) | 48 (20.2) | 27 (11.3) | |||
| Lymph node metastasis | 0.743 | 0.150 | ||||||
| Yes | 128 (53.8) | 52 (21.8) | 76 (31.9) | 99 (41.6) | 29 (12.2) | |||
| No | 110 (46.2) | 47(19.7) | 63 (26.5) | 76 (31.9) | 34 (14.3) | |||
| Pathological type | 0.338 | 0.032 | ||||||
| Adenocarcinoma | 155 (65.1) | 61 (25.6) | 94 (39.5) | 107 (45.0) | 48 (20.2) | |||
| Non-adenocarcinoma | 83 (34.9) | 38 (16.0) | 45 (18.9) | 68 (28.6) | 15 (6.3) | |||
| Degree of differentiation | 0.357 | 0.099 | ||||||
| Well + moderate | 178 (74.8) | 71 (29.8) | 107 (45.0) | 126 (52.9) | 52 (21.8) | |||
| Poor | 60 (25.2) | 28 (11.8) | 32 (13.4) | 49 (20.6) | 11 (4.6) | |||
| Pathological stage | 0.400 | 0.320 | ||||||
| IA–IIB | 154 (64.7) | 61 (25.6) | 93 (39.1) | 110 (46.2) | 44 (18.5) | |||
| IIIA–IV | 84 (35.3) | 38 (16.0) | 46(19.3) | 65 (27.3) | 19 (8.0) | |||
P<0.05 was statistically significant. HALP, hemoglobin, albumin, lymphocyte, and platelet; LMR, lymphocyte-to-monocyte ratio.